History of Shingles (Herpes Zoster): From Ancient "Zona" to Modern Vaccines

Shingles (herpes zoster) is the reactivation of latent varicella-zoster virus (VZV) from dorsal root ganglia after primary chickenpox infection.

Historical Milestones

• Ancient: Hippocrates (~400 BCE) described "zōnē" (girdle) — dermatomal vesicular eruption.
• TCM: "Fire of the liver/gallbladder"; treated with herbs.
• Middle Ages: "Holy fire" / "St. Anthony's fire" (confused with ergotism).
• 1767: William Heberden distinguished shingles from smallpox.
• 1831: Richard Bright noted chickenpox-shingles link.
• 1888: Von Bókay demonstrated chickenpox transmission from shingles vesicles.
• 1953: Weller isolated VZV in cell culture.
• 1965: Hope-Simpson proposed reactivation hypothesis.
• 1995: Live attenuated zoster vaccine (Zostavax) licensed.
• 2017: Recombinant zoster vaccine (Shingrix, RZV) — >90% efficacy, preferred for ≥50 years.

Current Landscape

• 1 in 3 lifetime risk; increases sharply >50 years.
• Postherpetic neuralgia (PHN) = pain >90 days post-rash; 10–18% of cases.
• Antivirals (valacyclovir 1g TID × 7d) within 72h reduce severity/PHN.
• Shingrix 2-dose series recommended for all ≥50 and immunocompromised ≥19.

From mysticism to molecular virology — shingles exemplifies medical progress.